Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia

Leukemia

Volumn 26, Issue 2, 2012, Pages 289-295

  Damm, F ^a   Bunke, T ^a   Thol, F ^a   Markus, B ^a   Wagner, K ^a   Gohring G ^a   Schlegelberger, B ^a   Heil, G ^a,b   Reuter, C W M ^a   Pullmann K ^a   Schlenk, R F ^c   Dohner K ^c   Heuser, M ^a   Krauter, J ^a   Dohner H ^c   Ganser, A ^a   Morgan, M A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum Ludenscheid   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

AML; DNMT3A; mutation; ND4; prognostication

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE 4; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; BASE SEQUENCE; DISEASE-FREE SURVIVAL; DNA PRIMERS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NADH DEHYDROGENASE; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856717197     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.200     Document Type: Article

References (42)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136. (Pubitemid 38380667)
3. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
4. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
5. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
6. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
7. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol 2009; 19: 57-66.
8. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25: 4647-4662. (Pubitemid 44187615)
9. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348: 2656-2668. (Pubitemid 36741594)
10. Ishikawa K, Hayashi J. A novel function of mtDNA: its involvement in metastasis. Ann NY Acad Sci 2010; 1201: 40-43.
11. Lee HC, Chang CM, Chi CW. Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev 2010; 9 (Suppl 1): S47-S58.
12. Piccoli C, RipoliM, Scrima R, Stanziale P, Di IanniM, Moretti L et al. MtDNA mutation associated with mitochondrial dysfunction in megakaryoblastic leukaemic cells. Leukemia 2008; 22: 1938-1941.
13. Manea EM, Leverger G, Bellmann F, Stanescu PA, Mircea A, Lebre AS et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J Pediatr Hematol Oncol 2009; 31: 947-951.
14. He L, Luo L, Proctor SJ, Middleton PG, Blakely EL, Taylor RW et al. Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia 2003; 17: 2487-2491. (Pubitemid 38072588)
15. Yao YG, Ogasawara Y, Kajigaya S, Molldrem JJ, Falcao RP, Pintao MC et al. Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 2007; 109: 756-762. (Pubitemid 46105978)
16. Torres-Bacete J, Nakamaru-Ogiso E, Matsuno-Yagi A, Yagi T. Characterization of the NuoM (ND4) subunit in Escherichia coli NDH-1: conserved charged residues essential for energy-coupled activities. J Biol Chem 2007; 282: 36914-36922.
17. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28: 2101-2107.
18. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged o/60 years: results of a prospective multicenter trial. Ann Hematol 2004; 83: 336-344. (Pubitemid 38684445)
19. Mitelman F. ISCN (1995): An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, Switzerland, 1995.
20. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010; 28: 2356-2364.
21. Thol F, Damm F,Wagner K, Gohring G, Schlegelberger B, Hoelzer D et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614-616.
22. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M et al. Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. J Clin Oncol 2011; 29: 2889-2896.
23. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633. (Pubitemid 41095065)
24. Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Gohring G et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010; 28: 578-585.
25. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007; 25: 3739-3745. (Pubitemid 47376607)
26. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25: 3337-3343. (Pubitemid 47325620)
27. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898-3905. (Pubitemid 44864574)
28. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009; 27: 3198-3204.
29. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A et al. Prognostic importance of histone methyltransferase Mixed Lineage Leukemia 5 (MLL5) expression in acute myeloid leukemia. J Clin Oncol 2011; 29: 682-689.
30. Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639-1647. (Pubitemid 47443982)
31. Damm F, Heuser M, Morgan M, Wagner K, Gorlich K, Grosshennig A et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011; 117: 4561-4568.
32. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
33. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255-260.
34. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333. (Pubitemid 28452973)
35. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
36. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer. Nat Med 2011; 17: 291-293.
37. Lerner F, Niere M, Ludwig A, Ziegler M. Structural and functional characterization of human NAD kinase. Biochem Biophys Res Commun 2001; 288: 69-74. (Pubitemid 32999726)
38. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
39. XuW, YangH, Liu Y, Yang Y,Wang P, KimSHet al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutaratedependent dioxygenases. Cancer Cell 2011; 19: 17-30.
40. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 2008; 14: 2270-2275. (Pubitemid 351551057)
41. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
42. Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001; 20: 5195-5198. (Pubitemid 32844048)